Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 3:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 156 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: High-dose influenza virus vaccine Clear all
Completed Phase 3 Interventional Results available

Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza

NCT02635724
View directory record Official record
Conditions
Influenza
Interventions
Peramivir
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Brooksville, Florida • Lakeland, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 8, 2026, 3:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults

NCT05755620
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Quadrivalent Inactivated Vaccine, Sodium Chloride, 0.9%, VRC-FLUNPF099-00-VP (H1ssF_3928)
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 8, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

NCT05071313
View directory record Official record
Conditions
Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention
Interventions
Ad26.RSV.preF-based vaccine, Quadrivalent High-dose Influenza Vaccine, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
65 Years and older
Enrollment
777 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
19
States / cities
Long Beach, California • Hollywood, Florida • Port Orange, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 8, 2026, 3:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Simultaneous RZV and aIIV4 Vaccination

NCT05007041
View directory record Official record
Conditions
Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event
Interventions
FLUAD® Quadrivalent, Fluzone® High-Dose Quadrivalent, SHINGRIX®
Biological
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 8, 2026, 3:14 AM EDT
Completed Phase 2 Interventional Results available

Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine

NCT04025580
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Flucelvax, Fluvirin, Fluzone High Dose
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 8, 2026, 3:14 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Higher Dose Intradermal H5 Vaccine

NCT00439335
View directory record Official record
Conditions
Influenza
Interventions
Inactivated Influenza A Vaccine A/H5N1, Placebo (IM), Placebo (ID)
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
227 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Oct 8, 2026, 3:14 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults

NCT01991587
View directory record Official record
Conditions
Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions
Low dose of quadrivalent VLP vaccine, Medium dose of quadrivalent VLP vaccine, High dose of quadrivalent VLP vaccine, Placebo
Biological
Lead sponsor
Medicago
Industry
Eligibility
18 Years to 49 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 8, 2026, 3:14 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)

NCT07159763
View directory record Official record
Conditions
Influenza
Interventions
MK-1406, Placebo
Combination Product
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
12 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
240
States / cities
Anniston, Alabama • Cullman, Alabama • Glendale, Arizona + 109 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 8, 2026, 3:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations

NCT02908269
View directory record Official record
Conditions
Influenza
Interventions
Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative, Fluzone High-Dose, vaccine, 2016-2017 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
3 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Bardstown, Kentucky • Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 8, 2026, 3:14 AM EDT
Completed Not applicable Interventional

Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients

NCT05663463
View directory record Official record
Conditions
Solid Organ Transplant
Interventions
Fluzone High-Dose - 2 doses, Fluzone High-Dose - 1 dose of HD
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 8, 2026, 3:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults

NCT02563093
View directory record Official record
Conditions
Influenza
Interventions
Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative, Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation, Fluzone High-Dose vaccine, 2015-2016 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
4
States / cities
Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Oct 8, 2026, 3:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety and Immunogenicity of H1N1 Vaccine

NCT01177202
View directory record Official record
Conditions
H1N1 Flu
Interventions
HAC1 Vaccine
Biological
Lead sponsor
Fraunhofer, Center for Molecular Biotechnology
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Oct 8, 2026, 3:14 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age

NCT04544267
View directory record Official record
Conditions
Influenza
Interventions
Quadrivalent influenza vaccine, high-dose, Quadrivalent influenza vaccine, standard dose
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 35 Months
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
10
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 8, 2026, 3:14 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults

NCT04101838
View directory record Official record
Conditions
Influenza
Interventions
Fluzone, Flucelvax, Fluzone High-Dose, Fluad
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 8, 2026, 3:14 AM EDT
Recruiting Phase 2 Interventional

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

NCT01804634
View directory record Official record
Conditions
Refractory and/or Relapsed Metastatic Solid Tumors
Interventions
Cyclophosphamide, Fludarabine, low dose total body irradiation, Melphalan, Tacrolimus
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
1 Year to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
3
States / cities
Baltimore, Maryland • The Bronx, New York • Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 8, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US

NCT03282240
View directory record Official record
Conditions
Influenza
Interventions
QIV-HD, Licensed TIV-HD1, Investigational TIV-HD2
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
2,670 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
36
States / cities
Anaheim, California • Redding, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 8, 2026, 3:14 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

NCT05553301
View directory record Official record
Conditions
Influenza Immunization
Interventions
Quadrivalent Influenza mRNA Vaccine MRT5407, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza High-Dose Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
23
States / cities
Rolling Hills Estates, California • San Diego, California • DeLand, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 8, 2026, 3:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults

NCT01427309
View directory record Official record
Conditions
Influenza
Interventions
High Dose Trivalent Inactivated Influenza Vaccine, Trivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
31,989 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
105
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Oct 8, 2026, 3:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of an Oral Vaccine to Prevent Avian Influenza

NCT01335347
View directory record Official record
Conditions
Avian Influenza, Bird Flu
Interventions
ND1.1, Placebo control
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 8, 2026, 3:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Three Licensed Influenza Vaccines

NCT03068949
View directory record Official record
Conditions
Influenza
Interventions
FluBlok, Fluzone, FluCelVax, Fluzone HD
Biological
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 49 Years
Enrollment
413 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 8, 2026, 3:14 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics

NCT07169318
View directory record Official record
Conditions
Influenza
Interventions
Placebo for VNT-101, VNT-101
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 8, 2026, 3:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults

NCT04896086
View directory record Official record
Conditions
Influenza, Seasonal Influenza
Interventions
VRC-GENADJ0110-AP-NV (Adjuplex), Flucelvax, VRC-FLUMOS0111-00-VP (FluMos-v1)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 8, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age

NCT06060457
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Placebo, mRNA-1345, Fluzone HD
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
65 Years and older
Enrollment
1,900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
34
States / cities
Scottsdale, Arizona • Dublin, California • Riverside, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 8, 2026, 3:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

NCT02553343
View directory record Official record
Conditions
Influenza
Interventions
High-dose quadrivalent influenza virus vaccine, High-dose influenza virus vaccine, High-dose trivalent inactivated influenza vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
792 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
9
States / cities
Milford, Connecticut • Coral Gables, Florida • Wichita, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2018 · Synced Oct 8, 2026, 3:14 AM EDT